• Je něco špatně v tomto záznamu ?

Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias

C. Mark, S. Meshinchi, B. Joyce, B. Gibson, C. Harrison, AK. Bergmann, BF. Goemans, CJH. Pronk, H. Lapillonne, G. Leverger, E. Antoniou, M. Schneider, A. Attarbaschi, M. Dworzak, J. Stary, D. Tomizawa, S. Ebert, M. Lejman, EA. Kolb, K....

. 2024 ; 204 (2) : 576-584. [pub] 20230924

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu multicentrická studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007442

Grantová podpora
Toronto Hospital for Sick Children

The prognostic impact of PICALM::MLLT10 status in childhood leukaemia is not well described. Ten International Berlin Frankfurt Münster-affiliated study groups and the Children's Oncology Group collaborated in this multicentre retrospective study. The presence of the PICALM::MLLT10 fusion gene was confirmed by fluorescence in situ hybridization and/or RNA sequencing at participating sites. Ninety-eight children met the study criteria. T-cell acute lymphoblastic leukaemia (T-ALL) and acute myeloid leukaemia (AML) predominated 55 (56%) and 39 (40%) patients, respectively. Most patients received a chemotherapy regimen per their disease phenotype: 58% received an ALL regimen, 40% an AML regimen and 1% a hybrid regimen. Outcomes for children with PICALM::MLLT10 ALL were reasonable: 5-year event-free survival (EFS) 67% and 5-year overall survival (OS) 76%, but children with PICALM::MLLT10 AML had poor outcomes: 5-year EFS 22% and 5-year OS 26%. Haematopoietic stem cell transplant (HSCT) did not result in a significant improvement in outcomes for PICALM::MLLT10 AML: 5-year EFS 20% for those who received HSCT versus 23% for those who did not (p = 0.6) and 5-year OS 37% versus 36% (p = 0.7). In summary, this study confirms that PICALM::MLLT10 AML is associated with a dismal prognosis and patients cannot be salvaged with HSCT; exploration of novel therapeutic options is warranted.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007442
003      
CZ-PrNML
005      
20240423155948.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.19067 $2 doi
035    __
$a (PubMed)37743097
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mark, Catherine $u Division of Hematology/Oncology, Toronto Hospital for Sick Children, Toronto, Ontario, Canada $1 https://orcid.org/0000000186502519
245    10
$a Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias / $c C. Mark, S. Meshinchi, B. Joyce, B. Gibson, C. Harrison, AK. Bergmann, BF. Goemans, CJH. Pronk, H. Lapillonne, G. Leverger, E. Antoniou, M. Schneider, A. Attarbaschi, M. Dworzak, J. Stary, D. Tomizawa, S. Ebert, M. Lejman, EA. Kolb, K. Schmiegelow, H. Hasle, O. Abla
520    9_
$a The prognostic impact of PICALM::MLLT10 status in childhood leukaemia is not well described. Ten International Berlin Frankfurt Münster-affiliated study groups and the Children's Oncology Group collaborated in this multicentre retrospective study. The presence of the PICALM::MLLT10 fusion gene was confirmed by fluorescence in situ hybridization and/or RNA sequencing at participating sites. Ninety-eight children met the study criteria. T-cell acute lymphoblastic leukaemia (T-ALL) and acute myeloid leukaemia (AML) predominated 55 (56%) and 39 (40%) patients, respectively. Most patients received a chemotherapy regimen per their disease phenotype: 58% received an ALL regimen, 40% an AML regimen and 1% a hybrid regimen. Outcomes for children with PICALM::MLLT10 ALL were reasonable: 5-year event-free survival (EFS) 67% and 5-year overall survival (OS) 76%, but children with PICALM::MLLT10 AML had poor outcomes: 5-year EFS 22% and 5-year OS 26%. Haematopoietic stem cell transplant (HSCT) did not result in a significant improvement in outcomes for PICALM::MLLT10 AML: 5-year EFS 20% for those who received HSCT versus 23% for those who did not (p = 0.6) and 5-year OS 37% versus 36% (p = 0.7). In summary, this study confirms that PICALM::MLLT10 AML is associated with a dismal prognosis and patients cannot be salvaged with HSCT; exploration of novel therapeutic options is warranted.
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a fúzní onkogenní proteiny $x genetika $7 D015514
650    _2
$a výsledek terapie $7 D016896
650    12
$a akutní myeloidní leukemie $x genetika $7 D015470
650    _2
$a transkripční faktory $x genetika $7 D014157
650    _2
$a akutní nemoc $7 D000208
650    _2
$a prognóza $7 D011379
650    12
$a monomerní proteiny vytvářející klathrin $x genetika $7 D034041
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Meshinchi, Soheil $u Fred Hutchinson Cancer Research Centre, Seattle, Washington, USA
700    1_
$a Joyce, Brooklyn $u Division of Hematology/Oncology, Toronto Hospital for Sick Children, Toronto, Ontario, Canada
700    1_
$a Gibson, Brenda $u Royal Hospital for Sick Children, Glasgow, Scotland, UK
700    1_
$a Harrison, Christine $u Newcastle University Centre for Cancer, Newcastle, UK
700    1_
$a Bergmann, Anke K $u Human Genetics, Hannover Medical School, Hannover, Germany
700    1_
$a Goemans, Bianca F $u Princess Maxima Centre for Pediatric Oncology, Utrecht, The Netherlands
700    1_
$a Pronk, Cornelis Jan H $u Skane University Hospital, Lund, Sweden
700    1_
$a Lapillonne, Helene $u Hôpital d'enfants Armand Trousseau, Paris, France
700    1_
$a Leverger, Guy $u Hôpital d'enfants Armand Trousseau, Paris, France
700    1_
$a Antoniou, Evangelia $u Universitats-Klinikum, Essen, Germany
700    1_
$a Schneider, Markus $u Universitats-Klinikum, Essen, Germany
700    1_
$a Attarbaschi, Andishe $u Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $1 https://orcid.org/0000000292856898
700    1_
$a Dworzak, Michael $u Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $1 https://orcid.org/0000000281751097
700    1_
$a Stary, Jan $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Tomizawa, Daisuke $u Division of Leukemia and Lymphoma, Children's Cancer Centre, National Centre for Child Health and Development, Tokyo, Japan
700    1_
$a Ebert, Sabine $u Clinic of Pediatric Hematology and Oncology, University Medical Centre, Hamburg, Germany
700    1_
$a Lejman, Monika $u Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, Lublin, Poland
700    1_
$a Kolb, E Anders $u Nemours Children's Hospital, Wilmington, Delaware, USA
700    1_
$a Schmiegelow, Kjeld $u Rigshospitalet University Hospital, Copenhagen, Denmark
700    1_
$a Hasle, Henrik $u Hematology/Oncology, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Abla, Oussama $u Division of Hematology/Oncology, Toronto Hospital for Sick Children, Toronto, Ontario, Canada
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 204, č. 2 (2024), s. 576-584
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37743097 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155945 $b ABA008
999    __
$a ok $b bmc $g 2081432 $s 1217209
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 204 $c 2 $d 576-584 $e 20230924 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
GRA    __
$p Toronto Hospital for Sick Children
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace